MAUNA KEA TECHNOLOGIES announces strong presence at Digestive Disease Week 2017

27 new oral communications and posters presented in the framework of the scientific programme, with a particular focus on the use of confocal laser endomicroscopy in Barrett’s esophagus and cysts pancreatic

Download the free guide
Boost your gains

The Cellvizio is presented at booth n°2644 of Mauna Kea during the conference DDW

Paris, may 9, 2017 19: 00 – Mauna Kea Technologies (Euronext : MKEA, OTCQX : MKEAY), inventor of Cellvizio®, the platform’s multidisciplinary confocal laser endomicroscopy, announced today that physicians will present clinical results obtained with confocal laser endomicroscopy (CLE) in 27 oral communications and posters in the framework of the conference DDW (Digestive Disease Week) in 2017, which will take place from the 6th to the 9th may 2017 at the McCormick Place in Chicago, Illinois. DDW is the largest educational forum global gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Sacha Loiseau, Founder and ceo of Mauna Kea Technologies, said, ” Our participation at the conference DDW has always been remarkable and this year, will not depart from this rule with 27 communications made by physicians on the current applications and emerging of the Cellvizio, with a particular emphasis on its use in the diagnosis of Barrett’s esophagus, and the cystic lesions of the pancreas. This increasing amount of data from clinical and medico-economic plays a crucial role in making even better aware of and adopt the technology of the Cellvizio. This is all the more important today as we introduce our model of a billing procedure that allows surgeons and gastroenterologists to embrace technology without capital investment. This new model is expected to be a growth engine for the use of the Cellvizio in its main indications, as recommended by the medical societies and reimbursed, such as gastroesophageal reflux disease (GERD), Barrett’s esophagus, and the cystic lesions of the pancreas.”

Mauna Kea is proud to have contributed to the following projects carried out by the doctors :
– on Monday, May 8, from 10:30 to 10:45 in S403b Dr. Bertrand Napoleon of the Hospital Jean Mermoz in Lyon, France, presented his work on the diagnosis of cystic lesions of the pancreas.
– Tuesday, may 9, of 14h22 at 14h44 in S502, Dr. Napoleon will make a presentation on the nCLE in the pancreas cysts of entitlement to CME credits, a first at DDW, reflecting the growing importance of this application.
– on Tuesday, 9 may, Dr. Raj Shah of the University of Colorado at Denver, Colorado, will present a poster on the study registry prospective multicenter trial conducted in the United States on the confocal laser endomicroscopy by minisonde (pCLE) to distinguish the strictures biliary benign from malignant strictures in patients with primary sclerosing cholangitis (PSC).

To learn more about Cellvizio, see you at the stand n°2644 Mauna Kea Technologies during the conference DDW.

About Mauna Kea Technologies
Mauna Kea Technologies is a global company medical devices whose mission is to maximize the diagnostics and treatments by direct visualization at the cellular level. The the Company’s flagship product, Cellvizio, has received marketing agreements for a wide range of applications in more than 40 countries including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply